DF Dent & Co. Inc. Has $1.22 Million Stake in Mesa Laboratories, Inc. (MLAB)
DF Dent & Co. Inc. grew its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 38.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,494 shares of the medical instruments supplier’s stock after acquiring an additional 2,346 shares during the period. DF Dent & Co. Inc. owned about 0.23% of Mesa Laboratories worth $1,217,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Mesa Laboratories by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 2,564 shares of the medical instruments supplier’s stock valued at $367,000 after acquiring an additional 169 shares in the last quarter. State Street Corp boosted its holdings in Mesa Laboratories by 7.5% during the second quarter. State Street Corp now owns 56,252 shares of the medical instruments supplier’s stock worth $8,063,000 after buying an additional 3,943 shares in the last quarter. Voya Investment Management LLC purchased a new stake in Mesa Laboratories during the second quarter worth about $221,000. Dimensional Fund Advisors LP boosted its holdings in Mesa Laboratories by 3.7% during the second quarter. Dimensional Fund Advisors LP now owns 129,320 shares of the medical instruments supplier’s stock worth $18,532,000 after buying an additional 4,634 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Mesa Laboratories by 9.8% during the second quarter. Renaissance Technologies LLC now owns 87,271 shares of the medical instruments supplier’s stock worth $12,507,000 after buying an additional 7,771 shares in the last quarter. 67.02% of the stock is currently owned by institutional investors and hedge funds.
Mesa Laboratories, Inc. (NASDAQ:MLAB) traded up 1.94% during trading on Wednesday, hitting $156.02. 469 shares of the stock were exchanged. The stock’s 50-day moving average price is $142.34 and its 200-day moving average price is $141.46. The firm has a market cap of $587.42 million, a PE ratio of 53.62 and a beta of 0.49. Mesa Laboratories, Inc. has a 12-month low of $109.14 and a 12-month high of $169.80.
Mesa Laboratories (NASDAQ:MLAB) last announced its earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.17). Mesa Laboratories had a return on equity of 16.58% and a net margin of 11.31%. The firm had revenue of $22.67 million during the quarter, compared to analyst estimates of $22.90 million. On average, equities analysts expect that Mesa Laboratories, Inc. will post $2.74 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Thursday, November 30th will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.42%. The ex-dividend date of this dividend is Wednesday, November 29th. Mesa Laboratories’s payout ratio is 22.94%.
In other Mesa Laboratories news, Director H Stuart Campbell sold 1,000 shares of the firm’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $130.16, for a total value of $130,160.00. Following the completion of the transaction, the director now directly owns 42,366 shares in the company, valued at $5,514,358.56. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last quarter, insiders sold 8,610 shares of company stock valued at $1,176,809. Corporate insiders own 15.70% of the company’s stock.
A number of analysts recently commented on MLAB shares. Zacks Investment Research raised shares of Mesa Laboratories from a “strong sell” rating to a “buy” rating and set a $167.00 price objective on the stock in a report on Tuesday, October 3rd. BidaskClub downgraded shares of Mesa Laboratories from a “sell” rating to a “strong sell” rating in a report on Saturday, August 12th. Finally, TheStreet downgraded shares of Mesa Laboratories from a “b” rating to a “c+” rating in a report on Monday, July 31st.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
Receive News & Stock Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related stocks with our FREE daily email newsletter.